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anisms  all  play  a  role  in  cyst  formation.  In  addition,  c-METLETTER / Genito-urinary imaging
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Crizotinib  is  a  promising  anti-cancer  drug  acting  as  a
c-MET,  ALK  (anaplastic  lymphoma  kinase)  and  ROS1  (c-ros
oncogene  1)  inhibitor,  approved  for  treatment  of  stage
IV  ALK  rearranged  non-small  cell  lung  cancer  (NSCLC).
Recently,  crizotinib  was  associated  with  a  reduction  of  eGFR
(estimated  Glomerular  Filtration  Rate),  but  the  mechanism
is  still  unclear  [1].  Tubular  toxicity  was  described  as  a  cause
of  renal  insufﬁciency  [2].
In  the  crizotinib  package  leaﬂet,  under  ‘‘common  side
effects’’,  it  is  mentioned  that  renal  cysts  appear  in  1  to  10
out  of  100  patients.
This  case  report’s  main  objective  is  to  illustrate  this  side
effect  and  try  to  explain  the  mechanism  behind  the  cyst
formation.
Methods
We  systematically  reviewed  and  compared  baseline  studies
(ultrasounds  and  CT  scans)  and  studies  after  treatment  in  the
7  patients  treated  with  crizotinib  at  our  institution  last  year.
ResultsSeven  patients  were  treated  with  crizotinib  at  our  insti-
tution  last  year.  The  appearance  of  bilateral  renal  cysts
Figure 1. Ultrasonography (coronal and axial view): typical cyst, w
demarcated walls and acoustic enhancement behind cyst.
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onths  after  the  beginning  of  therapy.  These  cysts  were
lassiﬁed  as  Bosniak  II  lesions:  ovoid  in  shape,  anechoic
ithout  internal  echoes,  smooth  clearly  demarcated  walls,
coustic  enhancement  behind  cyst  on  ultrasound  (Fig.  1),
ear-water  density  lesion,  without  septa  or  calciﬁcation  or
nhancing  soft  tissue  areas  (Fig.  2).  Some  cysts  showed
inimal  wall  thickening  with  no  contrast  enhancement.
GFR  remained  stable  for  this  patient  during  the  whole
ollow-up.  The  cyst  size  ﬂuctuated  over  time  while  doses
f  crizotinib  were  modiﬁed  (Fig.  3).  Because  the  patient
ad  a  recent  history  of  breast  cancer  with  liver  and  brain
etastasis,  ultrasound-guided  biopsy  was  performed  on  the
ysts  and  conﬁrmed  the  inﬂammatory  nature  of  the  ﬂuid
‘‘inﬂammatory  macrophages,  lymphocytes  and  neutrophils
ithout  epithelial  or  other  suspect  cell’’).
iscussion
rizotinib  is  an  inhibitor  of  c-MET.  c-MET  activation  is  linked
o  cyst  formation  and  some  authors  suggest  that  inhibition
f  c-MET  can  be  used  for  polycystic  kidney  disease  treat-
ent  [3]. Recently,  the  speciﬁc  suppression  of  c-MET  in  the
idney  was  associated  with  an  increased  risk  for  acute  renal
nsufﬁciency.  It  was  associated  with  an  increase  in  apoptosis,
nﬂammation  and  macrophage  inﬁltration  [4].  These  mech-hich is ovoid, anechoic without internal echoes, smooth clearly
s  known  to  play  a  critical  role  in  tubulogenesis.  Absence  of
-MET  signaling  in  kidney  cells  culture  leads  to  formation  of
yst-like  structure  in  vitro  [5].  So,  cyst  formation  could  be
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Figure 2. CT scan with contrast: near-water density lesion, without septa or calciﬁcation or enhancing soft tissue areas, but a minimal
wall thickening with no contrast enhancement.
Figure 3. Cyst size ﬂuctuated over time, while doses of crizotinib were changed (08.13 baseline CT scan, 10.13, 01.13 and 07.13 scans).
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linked  to  the  tubular  toxicity  of  crizotinib  and/or  the  critical
role  of  c-MET  function  in  tubulogenesis.
Our  report  emphasizes  that  the  use  of  crizotinib  can  lead
to  renal  cysts  formation.  Future  works  should  determine
if  the  appearance  of  kidney  cysts  is  predictive  of  kidney
dysfunction.  A  close  monitoring  of  kidney  function  and  mor-
phology  is  therefore  mandatory  in  patients  treated  with
crizotinib.  Comparison  with  baseline  exams  is  important
because  renal  cysts,  a  common  imaging  ﬁnding  in  adults,
are  sometimes  not  mentioned  in  the  ﬁnal  radiology  report.
This  side  effect  should  be  known,  so  that  these  cysts  are  not
confused  with  cystic  metastasis  or  primary  renal  tumour  and
avoid  useless  investigations.
Conclusion
Renal  cysts  may  occur  in  patients  treated  with  crizotinib.  A
thorough  understanding  of  baseline  imaging  studies  is  essen-
tial  for  diagnosis.  The  clinical  signiﬁcance  of  cyst  formation
must  be  studied.  It  could  reﬂect  an  optimal  inhibition  of  c-
MET  that  could  predict  a  better  outcome  for  patients  treated
with  this  drug.
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